The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'

G Atalay; L Dirix; L Biganzoli; L Beex; M Nooij; D Cameron; C Lohrisch; T Cufer; J P Lobelle; M R Mattiaci; M Piccart; R Paridaens

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'

G Atalay, L Dirix, L Biganzoli, L Beex, M Nooij, D Cameron, C Lohrisch, T Cufer, J P Lobelle, M R Mattiaci, M Piccart, R Paridaens

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.

Original language	English
Pages (from-to)	211-7
Number of pages	7
Journal	Annals of Oncology
Volume	15
Issue number	2
Publication status	Published - Feb 2004

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Aged, 80 and over
Androstadienes
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Arteriosclerosis
Breast Neoplasms
Cholesterol
Enzyme Inhibitors
Female
Humans
Lipids
Middle Aged
Neoplasm Metastasis
Postmenopause
Risk Factors
Tamoxifen

Fingerprint

Dive into the research topics of 'The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients''. Together they form a unique fingerprint.

Cite this

Atalay, G., Dirix, L., Biganzoli, L., Beex, L., Nooij, M., Cameron, D., Lohrisch, C., Cufer, T., Lobelle, J. P., Mattiaci, M. R., Piccart, M., & Paridaens, R. (2004). The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology, 15(2), 211-7.

Atalay, G ; Dirix, L ; Biganzoli, L et al. / The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer : a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. In: Annals of Oncology. 2004 ; Vol. 15, No. 2. pp. 211-7.

@article{d8cbd4f835a441d689a98462fcc9dc06,

title = "The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'",

abstract = "The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.",

keywords = "Adult, Aged, Aged, 80 and over, Androstadienes, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Arteriosclerosis, Breast Neoplasms, Cholesterol, Enzyme Inhibitors, Female, Humans, Lipids, Middle Aged, Neoplasm Metastasis, Postmenopause, Risk Factors, Tamoxifen",

author = "G Atalay and L Dirix and L Biganzoli and L Beex and M Nooij and D Cameron and C Lohrisch and T Cufer and Lobelle, {J P} and Mattiaci, {M R} and M Piccart and R Paridaens",

year = "2004",

month = feb,

language = "English",

volume = "15",

pages = "211--7",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "2",

}

Atalay, G, Dirix, L, Biganzoli, L, Beex, L, Nooij, M, Cameron, D, Lohrisch, C, Cufer, T, Lobelle, JP, Mattiaci, MR, Piccart, M & Paridaens, R 2004, 'The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'', Annals of Oncology, vol. 15, no. 2, pp. 211-7.

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. / Atalay, G; Dirix, L; Biganzoli, L et al.
In: Annals of Oncology, Vol. 15, No. 2, 02.2004, p. 211-7.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer

T2 - a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'

AU - Atalay, G

AU - Dirix, L

AU - Biganzoli, L

AU - Beex, L

AU - Nooij, M

AU - Cameron, D

AU - Lohrisch, C

AU - Cufer, T

AU - Lobelle, J P

AU - Mattiaci, M R

AU - Piccart, M

AU - Paridaens, R

PY - 2004/2

Y1 - 2004/2

N2 - The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.

AB - The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Androstadienes

KW - Antineoplastic Agents, Hormonal

KW - Aromatase Inhibitors

KW - Arteriosclerosis

KW - Breast Neoplasms

KW - Cholesterol

KW - Enzyme Inhibitors

KW - Female

KW - Humans

KW - Lipids

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Postmenopause

KW - Risk Factors

KW - Tamoxifen

M3 - Article

C2 - 14760111

SN - 0923-7534

VL - 15

SP - 211

EP - 217

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology. 2004 Feb;15(2):211-7.